GLP-1 microdosing: smart strategy or social media experiment?

What did @realself actually say?

Registered nurse Michelle Malpic argues that GLP-1 microdosing, meaning doses as low as 0.05 to 0.125 mg of semaglutide, is "much more common than people realize" and driven partly by celebrity use. She frames it as a way to capture metabolic benefits and produce "slow and steady" weight loss over a longer timeline, rather than the rapid losses associated with full therapeutic doses. It is a neat pitch, but several of the clinical assumptions underneath it need scrutiny.

Does the science back this up?

Mostly no, at least not in any rigorous published trial. There is no peer-reviewed randomized controlled evidence showing that sub-therapeutic semaglutide doses produce meaningful metabolic benefits in humans. The STEP trial program (Wilding et al., 2021, NEJM) established efficacy at doses up to 2.4 mg weekly. Nothing in that program tested 0.05 mg. What we have instead are anecdotes, compounding pharmacy marketing, and extrapolation from pharmacodynamic curves.

Semaglutide's GLP-1 receptor occupancy is dose-dependent. A 2022 modeling paper by Knudsen and Lau in the Journal of Medicinal Chemistry confirmed that receptor engagement scales with plasma concentration. Cutting the dose to a fraction of the therapeutic range does not simply produce a gentler version of the same effect. It may produce very little receptor engagement at all. The claim that microdoses reliably elicit "metabolic benefits" is not supported by published human data.

What did they get wrong (or right)?

She got the standard dosing range roughly right. The FDA-approved titration for Ozempic starts at 0.25 mg weekly for the first four weeks, then moves upward, with Wegovy reaching 2.4 mg for weight management. Citing 0.25 mg as a starting point is accurate for the brand-name product.

Where she goes wrong is the implication that microdoses are a clinically validated alternative strategy. The phrase "elicit the metabolic benefits" presents an unproven assumption as settled fact. There is also a meaningful regulatory problem she skips entirely: Ozempic pens do not deliver 0.05 mg doses. The doses she describes are only achievable through compounded semaglutide, which is a separate substance not FDA-approved and not equivalent to the brand-name drug. Presenting microdosing as a simple variation on Ozempic use without that disclosure is, at minimum, incomplete. The "celebrities are doing it" framing adds zero clinical weight and arguably just legitimizes off-label compounded use without accountability.

The slow-and-steady weight loss rationale also inverts how the literature works. Faster early weight loss in GLP-1 trials has actually predicted better long-term outcomes in some analyses, not worse.

What should you actually know?

GLP-1 microdosing is not an FDA-approved protocol. It is an off-label, largely anecdotal practice that has spread through social media and compounding pharmacy channels. If someone is offering you semaglutide at 0.05 mg doses, they are almost certainly offering you a compounded product, not Ozempic. Those are not the same thing, and the FDA has specifically warned about safety and quality concerns with compounded semaglutide (FDA, 2024 drug shortage guidance).

That does not mean low-dose GLP-1 therapy is impossible or automatically dangerous. Some clinicians do titrate patients more slowly than the label suggests, especially those with significant side effect sensitivity. But that is a supervised clinical decision, not a microdosing strategy. The difference matters.

• No published RCT has tested semaglutide doses below 0.25 mg for weight or metabolic outcomes.
• The "slow and steady is better" framing lacks supporting citations and contradicts some trial data.
• Celebrity use is not a clinical reference point.
• Patients interested in lower-dose options should discuss titration schedules with a licensed prescriber, not base decisions on social media content.